EIK1005 alone or with pembrolizumab for advanced solid tumors
Tests EIK1005, alone and with pembrolizumab, in adults with advanced solid tumors.
Key facts
- Who runs it
- Eikon Therapeutics
- Where
- Doral, Fort Worth, Hialeah, Houston, Lake Success, Los Angeles, Morristown, New York, Plantation, and Tamarac, United StatesSee the 10 sitesAlso in 14 other countries, 35 sites
- Trial code
- Registry title
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 160 people, planned
- Started
- 20 Jan 2026
- Expected to end
- Mar 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- EIK1005
- pembrolizumab (KEYTRUDA® )
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumors that cannot be removed by surgery or have spread. Some parts need tumors with MSI-H or dMMR.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced solid tumor that cannot be removed by surgery and/or has spread, with disease that can be measured on scans. Life expectancy of at least 3 months. Good daily function (ECOG score 0 to 1).
- Earlier treatment
- In Part 1A, people must have had at least 1 standard treatment for advanced disease and then had it stop working or not tolerated it. People who had a Werner (WRN) inhibitor before cannot join.
- Biomarker or test result
- In Part 1B and Part 2, the tumor must be MSI-H or dMMR, confirmed locally. Archival tumor tissue not more than 3 years old is needed for central lab confirmation.
Main reasons for not taking part
- Has not recovered from side effects of earlier cancer treatment
- Previous treatment with a Werner (WRN) inhibitor
- Active brain or spinal fluid cancer spread; treated brain spread must be stable
- Active autoimmune disease treated in the past 2 years, or a lung inflammation (pneumonitis) needing steroids
- Active tuberculosis or an infection needing treatment through the body
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- is ≥ 18 years of age at the time of signing the informed consent
- has a life expectancy of at least 3 months
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1
- has an adequate organ and marrow function
Who cannot take part
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs)
- has received prior treatment with Werner (WRN) inhibitor
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general
- has known additional malignancy that is progressing or has required active treatment within the past 3 years
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment)
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
- has active tuberculosis
- has any active infections requiring systemic therapy
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which best describes how well you can look after yourself and be active?
- Has your doctor told you that the cancer cannot be removed by surgery, or that it has spread to other parts of the body?
Where in United States
Also in 14 other countries, 35 sites
- Omnicure Clinical ResearchDoral, United StatesContact: Ana C Mamede, PharmDTaking people
- START Dallas Fort WorthFort Worth, United StatesContact: Ana C Mamede, PharmDTaking people
- BioResearch PartnerHialeah, United StatesContact: Ana C Mamede, PharmDTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Ana C Mamede, PharmDTaking people
- START New York Long IslandLake Success, United StatesContact: Ana C Mamede, PharmDTaking people
- California Research Institute (CRI)Los Angeles, United StatesContact: Ana C Mamede, PharmDTaking people
- Morristown Medical CenterMorristown, United StatesContact: Ana C Mamede, PharmDTaking people
- Memorial Sloan Kettering Cancer Center MskccNew York, United StatesContact: Ana C Mamede, PharmDTaking people
- Florida Clinical Trials Group.Plantation, United StatesContact: Ana C Mamede, PharmDTaking people
- Florida Clinical Trials Group - TamaracTamarac, United StatesContact: Ana C Mamede, PharmDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
The 3 groups in the trial
- Part 1A (Dose escalation, Monotherapy)Treatment being tested
EIK1005 will be given as monotherapy in participants without alternative treatment options.
Treatment: EIK1005
- Part 1B (Dose escalation, Combination with pembrolizumab)Treatment being tested
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.
Treatment: EIK1005 and pembrolizumab (KEYTRUDA® )
- Part 2 (Dose optimization, Monotherapy)Treatment being tested
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.
Treatment: EIK1005
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
- Plain-language title
- EIK1005 alone or with pembrolizumab for advanced solid tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07262619, who can take part
- Record updated
- 30 October 2026